UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

<u>January 16, 2019</u> (Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact Name of Registrant as Specified in its Charter)

Delaware	1-11353	13-3757370
(State or other jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
358 South Main Street,		
Burlington, North Carolina	27215	336-229-1127
(Address of principal executive offices)	(Zip Code)	(Registrant's telephone number including area code)
Check the appropriate box below if the Form 8-K filing is in provisions:	ntended to simultaneously satisfy the filing	g obligation of the registrant under any of the following
] Written communication pursuant to Rule 425 under the	Securities Act (17 CFR 230.425)	
Soliciting material pursuant to Rule 14a-12 under the Ex	xchange Act (17 CFR 240.14a-12)	
] Pre-commencement communications pursuant to Rule 1	.4d-2(b) under the Exchange Act (17 CFR	240.14d-2(b))

Item 7.01 Regulation FD Disclosure

LabCorp® (NYSE: LH) will release its fourth quarter and full year 2018 financial results before the market opens on Thursday, Feb. 7, 2019, and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results. The earnings release and accompanying financial information will be posted on the LabCorp Investor Relations website.

Interested parties can access the conference call by dialing 844-634-1444 within the U.S. and Canada, or 1-615-247-0253 internationally, using the passcode 1669755. In addition, a real-time webcast of the conference call will be available on the LabCorp Investor Relations website.

An audio replay of the conference call will be available from 1:00 p.m. EDT on Feb. 7, 2019, until 11:30 a.m. EDT on Feb. 21, 2019, by dialing 855-859-2056 within the U.S. and Canada, or 1-404-537-3406 internationally, using the passcode 1669755. The webcast of the conference call will be archived and accessible through Jan. 31, 2020, on the LabCorp Investor Relations website.

Exhibit Index Exhibit 99.1 Press release of the Company, dated January 16, 2019

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<u>LABORATORY CORPORATION OF AMERICA HOLDINGS</u> Registrant

By: /s/ EDWARD T. DODSON

Edward T. Dodson Chief Accounting Officer

January 16, 2019

Exhibit 99.1

FOR IMMEDIATE RELEASE

LabCorp Contacts: Scott Frommer (investors)

+1 336-436-5076 **Investor@labcorp.com**

Pattie Kushner (media) +1 336-436-8263 Media@labcorp.com

LabCorp to Announce Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019

BURLINGTON, N.C., Jan. 16, 2019 - LabCorp® (NYSE: LH) will release its fourth quarter and full year 2018 financial results before the market opens on Thursday, Feb. 7, 2019, and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results. The earnings release and accompanying financial information will be posted on the <u>LabCorp Investor Relations website</u>.

Interested parties can access the conference call by dialing 844-634-1444 within the U.S. and Canada, or 1-615-247-0253 internationally, using the passcode 1669755. In addition, a real-time webcast of the conference call will be available on the <u>LabCorp Investor Relations website</u>.

An audio replay of the conference call will be available from 1:00 p.m. EDT on Feb. 7, 2019, until 11:30 a.m. EDT on Feb. 21, 2019, by dialing 855-859-2056 within the U.S. and Canada, or 1-404-537-3406 internationally, using the passcode 1669755. The webcast of the conference call will be archived and accessible through Jan. 31, 2020, on the <u>LabCorp Investor Relations website</u>.

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported net revenues of more than \$10 billion for 2017. To learn more about LabCorp, visit www.LabCorp.com, and to learn more about Covance Drug Development, visit www.LabCorp.com, and to learn more about Covance Drug Development, visit www.Covance.com.

Forward-Looking Statements

This press release contains forward-looking statements including but not limited the impact of various factors on operating and financial results, expected savings and synergies (including from the LaunchPad initiative and from acquisitions), and the opportunities for future growth. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, changes in testing guidelines or recommendations, adverse results in material litigation matters, the impact of changes in tax laws and regulations, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, employee relations, and the effect of exchange rate fluctuations. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company's Form 10-K for the year ended Dec. 31, 2017, and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company's filings with the SEC including the information in the Company's Form 10-K for the year ended Dec. 31, 2017, and subsequent Forms 10-Q, under the heading MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.